The new indication makes the cervical implant compatible with Attrax Putty, NuVasive’s synthetic bone graft substitute, according to a news release. The putty was first approved for thoracolumbar interbody fusion in December 2021.
“This clearance represents a significant milestone towards that goal, expanding our advanced materials combination of Modulus and Attrax Putty to our cervical interbody within the C360 portfolio,” Ryan Donahoe, NuVasive’s chief technology officer, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.